


DIVA

Trial design: Patients with saphenous vein graft lesions undergoing PCI were randomized to drug-eluting stents (DES; n = 292) vs. bare-metal stents (BMS; n = 305).



Results

- Target vessel failure at 12 months (cardiac death, target vessel MI, or target vessel revascularization): 17% of the DES group vs. 19% of the BMS group ($p = 0.67$)
- Deaths at median 2.7 years: 19% for DES vs. 17% for BMS ($p = 0.54$)

Conclusions

- Among patients with a saphenous vein graft lesion undergoing PCI, DES were not superior to BMS at preventing target vessel failure; outcomes were similar among all individual outcomes